LV13243B - Amlodipine bezylate tablets with improved stability - Google Patents
Amlodipine bezylate tablets with improved stability Download PDFInfo
- Publication number
- LV13243B LV13243B LVP-04-82A LV040082A LV13243B LV 13243 B LV13243 B LV 13243B LV 040082 A LV040082 A LV 040082A LV 13243 B LV13243 B LV 13243B
- Authority
- LV
- Latvia
- Prior art keywords
- weight
- tablets
- amlodipine
- active ingredient
- microcrystalline cellulose
- Prior art date
Links
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 59
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract description 67
- 239000004480 active ingredient Substances 0.000 claims abstract description 46
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 28
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 28
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 28
- 239000000314 lubricant Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 9
- 229960004005 amlodipine besylate Drugs 0.000 claims 5
- 239000008119 colloidal silica Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000011109 contamination Methods 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000007907 direct compression Methods 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003110 Primojel Polymers 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000414697 Tegra Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- QXUQBFKDWCFPFB-UHFFFAOYSA-L calcium;magnesium;octadecanoate Chemical compound [Mg+2].[Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O QXUQBFKDWCFPFB-UHFFFAOYSA-L 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105345A HU226642B1 (en) | 2001-12-17 | 2001-12-17 | Amlodipine bezylate tablets having extended stability and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13243B true LV13243B (en) | 2005-05-20 |
Family
ID=90000366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-04-82A LV13243B (en) | 2001-12-17 | 2004-07-16 | Amlodipine bezylate tablets with improved stability |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1458384B1 (es) |
| AT (1) | ATE333877T1 (es) |
| AU (1) | AU2002353242A1 (es) |
| BG (1) | BG108807A (es) |
| CZ (1) | CZ2004791A3 (es) |
| DE (1) | DE60213464T2 (es) |
| EA (1) | EA006826B1 (es) |
| ES (1) | ES2269787T3 (es) |
| HR (1) | HRP20040582B1 (es) |
| HU (1) | HU226642B1 (es) |
| LT (1) | LT5241B (es) |
| LV (1) | LV13243B (es) |
| PL (1) | PL370420A1 (es) |
| RS (1) | RS54304A (es) |
| SK (1) | SK2862004A3 (es) |
| UA (1) | UA74968C2 (es) |
| WO (1) | WO2003051364A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| JP4954961B2 (ja) * | 2008-10-06 | 2012-06-20 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| JP5689052B2 (ja) * | 2011-12-26 | 2015-03-25 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| EA030466B1 (ru) | 2012-02-17 | 2018-08-31 | Эгиш Дьёдьсердьяр Зрт. | Фармацевтическая композиция, обладающая улучшенной стабильностью |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE19857716A1 (de) * | 1998-12-15 | 2000-06-21 | Bayer Ag | Neue feste Formulierung von Metrifonat |
| WO2003032954A1 (en) * | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
-
2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
-
2002
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
- 2002-12-17 EP EP02788262A patent/EP1458384B1/en not_active Expired - Lifetime
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/en active IP Right Grant
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
-
2004
- 2004-06-23 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2004062A (en) | 2005-02-25 |
| HU226642B1 (en) | 2009-05-28 |
| SK2862004A3 (en) | 2004-11-03 |
| RS54304A (en) | 2006-12-15 |
| HRP20040582B1 (en) | 2007-08-31 |
| UA74968C2 (en) | 2006-02-15 |
| DE60213464T2 (de) | 2007-03-01 |
| DE60213464D1 (de) | 2006-09-07 |
| ATE333877T1 (de) | 2006-08-15 |
| CZ2004791A3 (cs) | 2004-10-13 |
| BG108807A (en) | 2005-03-31 |
| WO2003051364A1 (en) | 2003-06-26 |
| HRP20040582A2 (en) | 2005-02-28 |
| HUP0105345A2 (hu) | 2003-12-29 |
| EP1458384A1 (en) | 2004-09-22 |
| LT5241B (lt) | 2005-07-25 |
| PL370420A1 (en) | 2005-05-30 |
| ES2269787T3 (es) | 2007-04-01 |
| AU2002353242A1 (en) | 2003-06-30 |
| HUP0105345A3 (en) | 2007-08-28 |
| EP1458384B1 (en) | 2006-07-26 |
| EA006826B1 (ru) | 2006-04-28 |
| EA200400801A1 (ru) | 2004-12-30 |
| HUP0105345D0 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4718776B2 (ja) | ５ｈｔ４部分アゴニスト医薬組成物 | |
| JP6041591B2 (ja) | イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物 | |
| HU190619B (en) | Process for producing tablets with controlled dissolution of active ingredients | |
| CZ299411B6 (cs) | Farmaceutický matricový prípravek vytvárející hydrofilní gel a zpusob výroby tohoto prípravku | |
| EP1458384B1 (en) | Amlopidine bezylate tablets with improved stability | |
| KR20180106185A (ko) | 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물 | |
| US20030153617A1 (en) | Simvastatin dosage forms | |
| EP2559431A1 (en) | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide | |
| HU200924B (en) | Process for producing pharmaceutical compositions comprising terfenadine | |
| EP2179725A1 (en) | Pharmaceutical composition comprising levetiracetam | |
| EP0266707B1 (en) | Sustained release labetalol tablet | |
| JPWO2011158870A1 (ja) | 放出制御型の有核錠剤 | |
| AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| US4940580A (en) | Sustained release labetalol tablets | |
| RU2674978C2 (ru) | Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида | |
| JP2009538905A (ja) | 感湿性薬物を含んで成る安定性製剤及びその製造方法 | |
| EP1917973A1 (en) | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | |
| US20070281000A1 (en) | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof | |
| US20060030581A1 (en) | Mannitol formulation for integrin receptor antagonist | |
| MX2007016238A (es) | Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente de ph. | |
| RU2707286C1 (ru) | Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения | |
| EP3335703A1 (en) | Pharmaceutical composition comprising omarigliptin | |
| CA2343949A1 (en) | Benazepril hydrochloride tablet formulations | |
| JP2009542806A (ja) | 感湿性薬物及び第２薬物の組合せを含んで成る安定製剤及びその製造方法 | |
| KR20090016594A (ko) | 수분 민감성 약물(들)을 포함하는 안정한 제제 및 이의 제조 절차 |